logo
Share SHARE
FONT-SIZE Plus   Neg

Dolutegravir Demonstrates Non-inferiority To Raltegravir In HIV Treatment: GSK

Pharmaceutical giant GlaxoSmithKline Plc (GSK, GSK.L) on Monday said initial results from a late-stage study showed that investigational integrase inhibitor dolutegravir was not inferior to raltegravir, thus meeting the primary objective of the trial.

The results were announced by Shionogi-ViiV Healthcare LLC, a joint venture between ViiV Healthcare Ltd and Shionogi & Co., Ltd. ViiV Healthcare is an HIV company established by GlaxoSmithKline and Pfizer, Inc. (PFE).

Dolutegravir is an investigational integrase inhibitor, or INI, currently in development by Shionogi-ViiV Healthcare LLC for the treatment of HIV. It is currently the only once-daily, unboosted INI in late-stage clinical development. Integrase inhibitors block HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells.

The SPRING-2 Phase III study with dolutegravir was conducted in treatment-naïve adults with HIV-1. The primary objective was non-inferiority of dolutegravir to raltegravir.

The study was designed to compare the efficacy and safety of dolutegravir 50 mg administered once-daily to raltegravir 400 mg administered twice daily, both with two nucleoside reverse transcriptase inhibitors. Four hundred and eleven treatment-naïve study participants were randomised in each arm.

The primary endpoint of the study was the proportion of study participants with undetectable HIV-1 RNA through 48 weeks. Through 48 weeks, 88 percent of study participants on dolutegravir were virologically suppressed compared to 85 percent of participants on raltegravir.

The tolerability of dolutegravir was similar to that of raltegravir. Rates of adverse events led to withdrawal at 2 percent in both arms.

Drug-related nausea was reported by 10 percent of patients in each arm. No other adverse events related to study medication were reported by over 5 percent of participants in any arm.

SPRING-2 is the first of four Phase III studies due to be reported this year. Data from the clinical trials SINGLE, VIKING-3 and SAILING will be received in 2012, thus allowing further determination of the profile of dolutegravir.

"The SPRING-2 findings indicate that once daily unboosted dolutegravir may offer people living with HIV an additional treatment option in the future. These are the first large-scale safety and efficacy data in naïve patients, and we look forward to seeing further data in 2012 to build a more comprehensive picture of the role of dolutegravir," said Dr John Pottage, Chief Medical Officer, ViiV Healthcare.

Full results of the study, including the full results of the secondary endpoints, will be presented at an upcoming scientific meeting.

GSK.L is currently trading at 1,400.50 pence, up 4 pence or 0.29 percent, on a volume of 465,981 shares.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Taco Bell, a division of Yum! Brands Inc, is planning to test delivery of food items on college campuses, the Street reported. The move comes at a time the fast food chain seeks to leverage demand for its popular breakfast and dinner items. In an unusual incident, an Airbus operated by Singapore Airlines temporarily lost power on both its Rolls Royce engines during a flight and plunged almost 13,000 feet or 3.96 kilometers. However, pilots managed to save the Airbus through standard operational procedures and it continued on its routine path. Hormel Foods has agreed to buy organic meat products maker Applegate Farms LLC for about $775 million, as consumers increasingly use natural and organic foods in their diet.
comments powered by Disqus
Follow RTT